Metacrine Inc. (MTCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTCR Stock Price Chart Interactive Chart >
MTCR Price/Volume Stats
|Current price||$0.52||52-week high||$4.12|
|Prev. close||$0.50||52-week low||$0.35|
|Day high||$0.55||Avg. volume||1,461,343|
|50-day MA||$0.46||Dividend yield||N/A|
|200-day MA||$1.04||Market Cap||22.10M|
Metacrine Inc. (MTCR) Company Bio
Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.
Most Popular Stories View All
MTCR Latest News Stream
|Loading, please wait...|
MTCR Latest Social Stream
View Full MTCR Social Stream
Latest MTCR News From Around the Web
Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms. Millican will remain with the Company until March 31, 2022 to ensure a smooth transition. In addition, Mr. Michael York, currently senior vice president, business development and commercial strategy, h
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Metacrine (MTCR – Research Report) today. The company's shares closed last Friday at $0.49, close to its 52-week low of $0.44. According to TipRanks.com, Arce is a 5-star analyst with an average return of 15.6% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Metacrine has an analyst consensus of Hold, with a price target consensus of $1.25. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $11.00 and a one-year low of $0.44. Currently, Metacrine has an average volume of 3.5M.
Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2020 at $13/share. While NASH was originally Metacrine's priority, the Company abandoned the program back in October after a toxicology study flagged potential delay. Instead, it pushed their FXR agonist, MET642, into a Phase 2 trial for inflammatory bowel disease. Metacrine announced its reorganiz
U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug
Rise and shine, trader!
MTCR Price Returns